Department of Paediatrics, Monash University, Melbourne, VIC, Australia.
Monash Newborn, Monash Children's Hospital, Melbourne, VIC, Australia.
Pediatr Res. 2023 Nov;94(5):1714-1719. doi: 10.1038/s41390-023-02649-4. Epub 2023 May 17.
Paracetamol is commonly used for analgesia and patent ductus arteriosus (PDA) treatment in preterm infants. We aimed to evaluate early neurodevelopmental outcomes of extreme preterm infants exposed to paracetamol during their neonatal admission.
This retrospective cohort study included surviving infants born at <29 weeks gestation, or with a birth weight of <1000 grams. Neurodevelopmental outcomes studied were early cerebral palsy (CP) or high risk of CP diagnosis, Hammersmith Infant Neurological Examination (HINE) score and Prechtl General Movement Assessment (GMA) at 3-4 months corrected age.
Two hundred and forty-two infants were included, of which 123 were exposed to paracetamol. After adjusting for birth weight, sex and chronic lung disease, there were no significant associations between paracetamol exposure and early CP or high risk of CP diagnosis (aOR 1.46, 95% CI 0.61, 3.5), abnormal or absent GMA (aOR 0.82, 95% CI 0.37, 1.79) or HINE score (adjusted β -0.19, 95% CI -2.39, 2.01). Subgroup analysis stratifying paracetamol exposure into <180 mg/kg or ≥180 mg/kg cumulative dose found that neither had significant effects on outcomes.
In this cohort of extreme preterm infants, no significant association was found between exposure to paracetamol during the neonatal admission and adverse early neurodevelopment.
Paracetamol is commonly used in the neonatal period for analgesia and patent ductus arteriosus treatment in preterm infants, although prenatal paracetamol use has been associated with adverse neurodevelopmental outcomes. Exposure to paracetamol during the neonatal admission was not associated with adverse early neurodevelopment at 3-4 months corrected age in this cohort of extreme preterm infants. The findings from this observational study is consistent with the small body of literature supporting the lack of association between neonatal paracetamol exposure and adverse neurodevelopmental outcomes in preterm infants.
对早产儿而言,扑热息痛常用于镇痛和治疗动脉导管未闭(PDA)。我们旨在评估新生儿期暴露于扑热息痛的极早产儿的早期神经发育结局。
本回顾性队列研究纳入了出生胎龄<29 周或出生体重<1000 克的存活婴儿。研究的神经发育结局为早期脑瘫(CP)或 CP 高风险诊断、3-4 月龄校正年龄时的哈默史密斯婴儿神经检查(HINE)评分和普雷希特运动评估(GMA)。
共纳入 242 例婴儿,其中 123 例暴露于扑热息痛。在校正出生体重、性别和慢性肺部疾病后,扑热息痛暴露与早期 CP 或 CP 高风险诊断(aOR 1.46,95%CI 0.61,3.5)、异常或缺失 GMA(aOR 0.82,95%CI 0.37,1.79)或 HINE 评分(调整β-0.19,95%CI-2.39,2.01)之间均无显著关联。将扑热息痛暴露分层为<180mg/kg 或≥180mg/kg 累积剂量亚组分析发现,两者均对结局无显著影响。
在本极早产儿队列中,新生儿期暴露于扑热息痛与不良早期神经发育之间未发现显著关联。
扑热息痛在新生儿期常用于镇痛和治疗早产儿的动脉导管未闭,尽管产前扑热息痛的使用与不良神经发育结局相关。在本极早产儿队列中,新生儿期暴露于扑热息痛与 3-4 月龄校正年龄时的不良早期神经发育无关。本观察性研究的结果与少量支持新生儿期扑热息痛暴露与早产儿不良神经发育结局之间无关联的文献一致。